Global Viral Gene Therapy Market

Viral Gene Therapy Comprehensive Study by Vector Type (Viral Vector {Lentivirus, Adeno-Associated Virus, Retrovirus & Gamma retrovirus, Modified Herpes Simplex, Adenovirus Virus}, Non-Viral Vector {Oligonucleotides, non-viral vectors (plasmids and RNAi)), Distribution Channel (Hospitals, Clinics, Others), Method (IN Vivo, Ex-Vivo), Therapeutic Area (Cardiovascular Diseases, Genetic Disorders, Autoimmune Disorders, Dermatological Disorders, Metabolic Disorders, Hematological Disorders, Muscle-related Diseases, Oncological Disorders, Ophthalmic Disease) Players and Region - Global Market Outlook to 2026

Viral Gene Therapy Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Viral Gene Therapy Market Scope
Modified viruses are used as drug delivery vehicles to insert particular DNA sequences—encoding genes, regulatory RNAs, or other therapeutic substrates—into cells in viral-vector gene treatments. Gene therapies are potential treatments for a wide range of disorders, with the goal of fundamentally treating the diseases' origins rather than just alleviating the symptoms. They might help with a variety of previously treatable illnesses, including hematological, ophthalmic, neurological, and malignancies.

Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Viral Gene Therapy market throughout the predicted period.

Biogen (United States), Novartis AG (Switzerland), Gilead Sciences, Inc. (United States), Spark Therapeutics, Inc. (United States), Orchard Therapeutics plc. (United Kingdom), MolMed S.p.A. (Italy), AnGes, Inc. (Japan), Bluebird bio, Inc. (United States), Human Stem Cells Institute (Russia) and Dynavax Technologies (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Akcea Therapeutics (United States), Alnylam Pharmaceuticals, Inc. (United States) and Jazz Pharmaceuticals, Inc. (Ireland).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
The study have segmented the market of Global Viral Gene Therapy market and Region with country level break-up.

On the basis of geography, the market of Viral Gene Therapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Leaders and their expansionary development strategies
On 15 April 2019, Catalent acquire gene therapy leader Paragon Bioservices. This acquisition helps the company by transformative addition. Paragon offers an additional capacity to Catalent that will significantly improve our biologics business and end-to-end integrated biopharmaceutical solutions for clients. Paragon has unique skills in GMP plasmids and lentivirus vectors, as well as specific knowledge in adeno-associated virus (AAV) vectors, the most widely utilized delivery mechanism for gene therapy.
On 24 May 2019, AveXis, a Novartis company announced the approval of Zolgensma by USFDA for the treatment of pediatric patients less than 2 years of age suffering with spinal muscular atrophy with a bi-allelic mutation in the survival motor neuron gene. With a single, one-time intravenous infusion, Zolgensma is aimed to treat the genetic root cause of SMA by delivering a functional copy of the human SMN gene to prevent disease development through sustained SMN protein production. The FDA has authorized Zolgensma as the first and only gene therapy for the treatment of SMA, including those who are pre-symptomatic at the time of diagnosis.
“As per USFDA for therapeutic reasons, human gene therapy seeks to change the biological properties of live cells or modify the expression of a gene. All products that mediate their effects by transcription or translation of transferred genetic information or by explicitly changing host (human) genetic sequences are considered human gene therapy products by the FDA. Nucleic acids genetically modified microorganisms (e.g., viruses, bacteria, fungus), designed site-specific nucleases used for human genome editing, and ex vivo genetically changed human cells are all examples of gene therapy products. It should include a broad overview of the gene therapy product under research, as well as a description of the active ingredient(s), mechanism of action, and intended clinical use.”

Market Trend
  • Technological Advancement of Editing and Genome Therapy in Molecular and Cell Biology

Market Drivers
  • Demand for Viral Gene Therapy for the Treatment of Cancer and Neurosurgical Disease
  • Approval of Products Such as Zolgensma And Lentiglobin will propel the Viral Gene Therapy Market

Opportunities
  • Large Number of Medicines Currently Undergoing Clinical Testing and Government Investment in Gene Therapy Market Will Boost the Viral Gene Therapy Market

Restraints
  • High Cost of Gene Treatments and Undesired Immune Reactions Will Constrain the Viral Gene Therapy Market

Challenges
  • Infection and Possibilities of Tumor During Viral Gene Therapy is Challenge for the Viral Gene Therapy Market


Key Target Audience
Viral Gene Therapy Providers, Research and Development Institutes, Upstream and Downstream Buyers, Financial Institutes and Investors, Regulatory Bodies and Others

Report Objectives / Segmentation Covered

By Vector Type
  • Viral Vector {Lentivirus, Adeno-Associated Virus, Retrovirus & Gamma retrovirus, Modified Herpes Simplex, Adenovirus Virus}
  • Non-Viral Vector {Oligonucleotides, non-viral vectors (plasmids and RNAi)

By Distribution Channel
  • Hospitals
  • Clinics
  • Others

By Method
  • IN Vivo
  • Ex-Vivo

By Therapeutic Area
  • Cardiovascular Diseases
  • Genetic Disorders
  • Autoimmune Disorders
  • Dermatological Disorders
  • Metabolic Disorders
  • Hematological Disorders
  • Muscle-related Diseases
  • Oncological Disorders
  • Ophthalmic Disease

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Demand for Viral Gene Therapy for the Treatment of Cancer and Neurosurgical Disease
      • 3.2.2. Approval of Products Such as Zolgensma And Lentiglobin will propel the Viral Gene Therapy Market
    • 3.3. Market Challenges
      • 3.3.1. Infection and Possibilities of Tumor During Viral Gene Therapy is Challenge for the Viral Gene Therapy Market
    • 3.4. Market Trends
      • 3.4.1. Technological Advancement of Editing and Genome Therapy in Molecular and Cell Biology
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Viral Gene Therapy, by Vector Type, Distribution Channel, Method, Therapeutic Area and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Viral Gene Therapy (Value)
      • 5.2.1. Global Viral Gene Therapy by: Vector Type (Value)
        • 5.2.1.1. Viral Vector {Lentivirus, Adeno-Associated Virus, Retrovirus & Gamma retrovirus, Modified Herpes Simplex, Adenovirus Virus}
        • 5.2.1.2. Non-Viral Vector {Oligonucleotides, non-viral vectors (plasmids and RNAi)
      • 5.2.2. Global Viral Gene Therapy by: Distribution Channel (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Others
      • 5.2.3. Global Viral Gene Therapy by: Method (Value)
        • 5.2.3.1. IN Vivo
        • 5.2.3.2. Ex-Vivo
      • 5.2.4. Global Viral Gene Therapy by: Therapeutic Area (Value)
        • 5.2.4.1. Cardiovascular Diseases
        • 5.2.4.2. Genetic Disorders
        • 5.2.4.3. Autoimmune Disorders
        • 5.2.4.4. Dermatological Disorders
        • 5.2.4.5. Metabolic Disorders
        • 5.2.4.6. Hematological Disorders
        • 5.2.4.7. Muscle-related Diseases
        • 5.2.4.8. Oncological Disorders
        • 5.2.4.9. Ophthalmic Disease
      • 5.2.5. Global Viral Gene Therapy Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Viral Gene Therapy (Price)
  • 6. Viral Gene Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Biogen (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Gilead Sciences, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Spark Therapeutics, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Orchard Therapeutics plc. (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. MolMed S.p.A. (Italy)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. AnGes, Inc. (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bluebird bio, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Human Stem Cells Institute (Russia)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Dynavax Technologies (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Viral Gene Therapy Sale, by Vector Type, Distribution Channel, Method, Therapeutic Area and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Viral Gene Therapy (Value)
      • 7.2.1. Global Viral Gene Therapy by: Vector Type (Value)
        • 7.2.1.1. Viral Vector {Lentivirus, Adeno-Associated Virus, Retrovirus & Gamma retrovirus, Modified Herpes Simplex, Adenovirus Virus}
        • 7.2.1.2. Non-Viral Vector {Oligonucleotides, non-viral vectors (plasmids and RNAi)
      • 7.2.2. Global Viral Gene Therapy by: Distribution Channel (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Others
      • 7.2.3. Global Viral Gene Therapy by: Method (Value)
        • 7.2.3.1. IN Vivo
        • 7.2.3.2. Ex-Vivo
      • 7.2.4. Global Viral Gene Therapy by: Therapeutic Area (Value)
        • 7.2.4.1. Cardiovascular Diseases
        • 7.2.4.2. Genetic Disorders
        • 7.2.4.3. Autoimmune Disorders
        • 7.2.4.4. Dermatological Disorders
        • 7.2.4.5. Metabolic Disorders
        • 7.2.4.6. Hematological Disorders
        • 7.2.4.7. Muscle-related Diseases
        • 7.2.4.8. Oncological Disorders
        • 7.2.4.9. Ophthalmic Disease
      • 7.2.5. Global Viral Gene Therapy Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Viral Gene Therapy (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Viral Gene Therapy: by Vector Type(USD N)
  • Table 2. Viral Gene Therapy Viral Vector {Lentivirus, Adeno-Associated Virus, Retrovirus & Gamma retrovirus, Modified Herpes Simplex, Adenovirus Virus} , by Region USD N (2016-2021)
  • Table 3. Viral Gene Therapy Non-Viral Vector {Oligonucleotides, non-viral vectors (plasmids and RNAi) , by Region USD N (2016-2021)
  • Table 4. Viral Gene Therapy: by Distribution Channel(USD N)
  • Table 5. Viral Gene Therapy Hospitals , by Region USD N (2016-2021)
  • Table 6. Viral Gene Therapy Clinics , by Region USD N (2016-2021)
  • Table 7. Viral Gene Therapy Others , by Region USD N (2016-2021)
  • Table 8. Viral Gene Therapy: by Method(USD N)
  • Table 9. Viral Gene Therapy IN Vivo , by Region USD N (2016-2021)
  • Table 10. Viral Gene Therapy Ex-Vivo , by Region USD N (2016-2021)
  • Table 11. Viral Gene Therapy: by Therapeutic Area(USD N)
  • Table 12. Viral Gene Therapy Cardiovascular Diseases , by Region USD N (2016-2021)
  • Table 13. Viral Gene Therapy Genetic Disorders , by Region USD N (2016-2021)
  • Table 14. Viral Gene Therapy Autoimmune Disorders , by Region USD N (2016-2021)
  • Table 15. Viral Gene Therapy Dermatological Disorders , by Region USD N (2016-2021)
  • Table 16. Viral Gene Therapy Metabolic Disorders , by Region USD N (2016-2021)
  • Table 17. Viral Gene Therapy Hematological Disorders , by Region USD N (2016-2021)
  • Table 18. Viral Gene Therapy Muscle-related Diseases , by Region USD N (2016-2021)
  • Table 19. Viral Gene Therapy Oncological Disorders , by Region USD N (2016-2021)
  • Table 20. Viral Gene Therapy Ophthalmic Disease , by Region USD N (2016-2021)
  • Table 21. South America Viral Gene Therapy, by Country USD N (2016-2021)
  • Table 22. South America Viral Gene Therapy, by Vector Type USD N (2016-2021)
  • Table 23. South America Viral Gene Therapy, by Distribution Channel USD N (2016-2021)
  • Table 24. South America Viral Gene Therapy, by Method USD N (2016-2021)
  • Table 25. South America Viral Gene Therapy, by Therapeutic Area USD N (2016-2021)
  • Table 26. Brazil Viral Gene Therapy, by Vector Type USD N (2016-2021)
  • Table 27. Brazil Viral Gene Therapy, by Distribution Channel USD N (2016-2021)
  • Table 28. Brazil Viral Gene Therapy, by Method USD N (2016-2021)
  • Table 29. Brazil Viral Gene Therapy, by Therapeutic Area USD N (2016-2021)
  • Table 30. Argentina Viral Gene Therapy, by Vector Type USD N (2016-2021)
  • Table 31. Argentina Viral Gene Therapy, by Distribution Channel USD N (2016-2021)
  • Table 32. Argentina Viral Gene Therapy, by Method USD N (2016-2021)
  • Table 33. Argentina Viral Gene Therapy, by Therapeutic Area USD N (2016-2021)
  • Table 34. Rest of South America Viral Gene Therapy, by Vector Type USD N (2016-2021)
  • Table 35. Rest of South America Viral Gene Therapy, by Distribution Channel USD N (2016-2021)
  • Table 36. Rest of South America Viral Gene Therapy, by Method USD N (2016-2021)
  • Table 37. Rest of South America Viral Gene Therapy, by Therapeutic Area USD N (2016-2021)
  • Table 38. Asia Pacific Viral Gene Therapy, by Country USD N (2016-2021)
  • Table 39. Asia Pacific Viral Gene Therapy, by Vector Type USD N (2016-2021)
  • Table 40. Asia Pacific Viral Gene Therapy, by Distribution Channel USD N (2016-2021)
  • Table 41. Asia Pacific Viral Gene Therapy, by Method USD N (2016-2021)
  • Table 42. Asia Pacific Viral Gene Therapy, by Therapeutic Area USD N (2016-2021)
  • Table 43. China Viral Gene Therapy, by Vector Type USD N (2016-2021)
  • Table 44. China Viral Gene Therapy, by Distribution Channel USD N (2016-2021)
  • Table 45. China Viral Gene Therapy, by Method USD N (2016-2021)
  • Table 46. China Viral Gene Therapy, by Therapeutic Area USD N (2016-2021)
  • Table 47. Japan Viral Gene Therapy, by Vector Type USD N (2016-2021)
  • Table 48. Japan Viral Gene Therapy, by Distribution Channel USD N (2016-2021)
  • Table 49. Japan Viral Gene Therapy, by Method USD N (2016-2021)
  • Table 50. Japan Viral Gene Therapy, by Therapeutic Area USD N (2016-2021)
  • Table 51. India Viral Gene Therapy, by Vector Type USD N (2016-2021)
  • Table 52. India Viral Gene Therapy, by Distribution Channel USD N (2016-2021)
  • Table 53. India Viral Gene Therapy, by Method USD N (2016-2021)
  • Table 54. India Viral Gene Therapy, by Therapeutic Area USD N (2016-2021)
  • Table 55. South Korea Viral Gene Therapy, by Vector Type USD N (2016-2021)
  • Table 56. South Korea Viral Gene Therapy, by Distribution Channel USD N (2016-2021)
  • Table 57. South Korea Viral Gene Therapy, by Method USD N (2016-2021)
  • Table 58. South Korea Viral Gene Therapy, by Therapeutic Area USD N (2016-2021)
  • Table 59. Taiwan Viral Gene Therapy, by Vector Type USD N (2016-2021)
  • Table 60. Taiwan Viral Gene Therapy, by Distribution Channel USD N (2016-2021)
  • Table 61. Taiwan Viral Gene Therapy, by Method USD N (2016-2021)
  • Table 62. Taiwan Viral Gene Therapy, by Therapeutic Area USD N (2016-2021)
  • Table 63. Australia Viral Gene Therapy, by Vector Type USD N (2016-2021)
  • Table 64. Australia Viral Gene Therapy, by Distribution Channel USD N (2016-2021)
  • Table 65. Australia Viral Gene Therapy, by Method USD N (2016-2021)
  • Table 66. Australia Viral Gene Therapy, by Therapeutic Area USD N (2016-2021)
  • Table 67. Rest of Asia-Pacific Viral Gene Therapy, by Vector Type USD N (2016-2021)
  • Table 68. Rest of Asia-Pacific Viral Gene Therapy, by Distribution Channel USD N (2016-2021)
  • Table 69. Rest of Asia-Pacific Viral Gene Therapy, by Method USD N (2016-2021)
  • Table 70. Rest of Asia-Pacific Viral Gene Therapy, by Therapeutic Area USD N (2016-2021)
  • Table 71. Europe Viral Gene Therapy, by Country USD N (2016-2021)
  • Table 72. Europe Viral Gene Therapy, by Vector Type USD N (2016-2021)
  • Table 73. Europe Viral Gene Therapy, by Distribution Channel USD N (2016-2021)
  • Table 74. Europe Viral Gene Therapy, by Method USD N (2016-2021)
  • Table 75. Europe Viral Gene Therapy, by Therapeutic Area USD N (2016-2021)
  • Table 76. Germany Viral Gene Therapy, by Vector Type USD N (2016-2021)
  • Table 77. Germany Viral Gene Therapy, by Distribution Channel USD N (2016-2021)
  • Table 78. Germany Viral Gene Therapy, by Method USD N (2016-2021)
  • Table 79. Germany Viral Gene Therapy, by Therapeutic Area USD N (2016-2021)
  • Table 80. France Viral Gene Therapy, by Vector Type USD N (2016-2021)
  • Table 81. France Viral Gene Therapy, by Distribution Channel USD N (2016-2021)
  • Table 82. France Viral Gene Therapy, by Method USD N (2016-2021)
  • Table 83. France Viral Gene Therapy, by Therapeutic Area USD N (2016-2021)
  • Table 84. Italy Viral Gene Therapy, by Vector Type USD N (2016-2021)
  • Table 85. Italy Viral Gene Therapy, by Distribution Channel USD N (2016-2021)
  • Table 86. Italy Viral Gene Therapy, by Method USD N (2016-2021)
  • Table 87. Italy Viral Gene Therapy, by Therapeutic Area USD N (2016-2021)
  • Table 88. United Kingdom Viral Gene Therapy, by Vector Type USD N (2016-2021)
  • Table 89. United Kingdom Viral Gene Therapy, by Distribution Channel USD N (2016-2021)
  • Table 90. United Kingdom Viral Gene Therapy, by Method USD N (2016-2021)
  • Table 91. United Kingdom Viral Gene Therapy, by Therapeutic Area USD N (2016-2021)
  • Table 92. Netherlands Viral Gene Therapy, by Vector Type USD N (2016-2021)
  • Table 93. Netherlands Viral Gene Therapy, by Distribution Channel USD N (2016-2021)
  • Table 94. Netherlands Viral Gene Therapy, by Method USD N (2016-2021)
  • Table 95. Netherlands Viral Gene Therapy, by Therapeutic Area USD N (2016-2021)
  • Table 96. Rest of Europe Viral Gene Therapy, by Vector Type USD N (2016-2021)
  • Table 97. Rest of Europe Viral Gene Therapy, by Distribution Channel USD N (2016-2021)
  • Table 98. Rest of Europe Viral Gene Therapy, by Method USD N (2016-2021)
  • Table 99. Rest of Europe Viral Gene Therapy, by Therapeutic Area USD N (2016-2021)
  • Table 100. MEA Viral Gene Therapy, by Country USD N (2016-2021)
  • Table 101. MEA Viral Gene Therapy, by Vector Type USD N (2016-2021)
  • Table 102. MEA Viral Gene Therapy, by Distribution Channel USD N (2016-2021)
  • Table 103. MEA Viral Gene Therapy, by Method USD N (2016-2021)
  • Table 104. MEA Viral Gene Therapy, by Therapeutic Area USD N (2016-2021)
  • Table 105. Middle East Viral Gene Therapy, by Vector Type USD N (2016-2021)
  • Table 106. Middle East Viral Gene Therapy, by Distribution Channel USD N (2016-2021)
  • Table 107. Middle East Viral Gene Therapy, by Method USD N (2016-2021)
  • Table 108. Middle East Viral Gene Therapy, by Therapeutic Area USD N (2016-2021)
  • Table 109. Africa Viral Gene Therapy, by Vector Type USD N (2016-2021)
  • Table 110. Africa Viral Gene Therapy, by Distribution Channel USD N (2016-2021)
  • Table 111. Africa Viral Gene Therapy, by Method USD N (2016-2021)
  • Table 112. Africa Viral Gene Therapy, by Therapeutic Area USD N (2016-2021)
  • Table 113. North America Viral Gene Therapy, by Country USD N (2016-2021)
  • Table 114. North America Viral Gene Therapy, by Vector Type USD N (2016-2021)
  • Table 115. North America Viral Gene Therapy, by Distribution Channel USD N (2016-2021)
  • Table 116. North America Viral Gene Therapy, by Method USD N (2016-2021)
  • Table 117. North America Viral Gene Therapy, by Therapeutic Area USD N (2016-2021)
  • Table 118. United States Viral Gene Therapy, by Vector Type USD N (2016-2021)
  • Table 119. United States Viral Gene Therapy, by Distribution Channel USD N (2016-2021)
  • Table 120. United States Viral Gene Therapy, by Method USD N (2016-2021)
  • Table 121. United States Viral Gene Therapy, by Therapeutic Area USD N (2016-2021)
  • Table 122. Canada Viral Gene Therapy, by Vector Type USD N (2016-2021)
  • Table 123. Canada Viral Gene Therapy, by Distribution Channel USD N (2016-2021)
  • Table 124. Canada Viral Gene Therapy, by Method USD N (2016-2021)
  • Table 125. Canada Viral Gene Therapy, by Therapeutic Area USD N (2016-2021)
  • Table 126. Mexico Viral Gene Therapy, by Vector Type USD N (2016-2021)
  • Table 127. Mexico Viral Gene Therapy, by Distribution Channel USD N (2016-2021)
  • Table 128. Mexico Viral Gene Therapy, by Method USD N (2016-2021)
  • Table 129. Mexico Viral Gene Therapy, by Therapeutic Area USD N (2016-2021)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Viral Gene Therapy: by Vector Type(USD N)
  • Table 141. Viral Gene Therapy Viral Vector {Lentivirus, Adeno-Associated Virus, Retrovirus & Gamma retrovirus, Modified Herpes Simplex, Adenovirus Virus} , by Region USD N (2021-2026)
  • Table 142. Viral Gene Therapy Non-Viral Vector {Oligonucleotides, non-viral vectors (plasmids and RNAi) , by Region USD N (2021-2026)
  • Table 143. Viral Gene Therapy: by Distribution Channel(USD N)
  • Table 144. Viral Gene Therapy Hospitals , by Region USD N (2021-2026)
  • Table 145. Viral Gene Therapy Clinics , by Region USD N (2021-2026)
  • Table 146. Viral Gene Therapy Others , by Region USD N (2021-2026)
  • Table 147. Viral Gene Therapy: by Method(USD N)
  • Table 148. Viral Gene Therapy IN Vivo , by Region USD N (2021-2026)
  • Table 149. Viral Gene Therapy Ex-Vivo , by Region USD N (2021-2026)
  • Table 150. Viral Gene Therapy: by Therapeutic Area(USD N)
  • Table 151. Viral Gene Therapy Cardiovascular Diseases , by Region USD N (2021-2026)
  • Table 152. Viral Gene Therapy Genetic Disorders , by Region USD N (2021-2026)
  • Table 153. Viral Gene Therapy Autoimmune Disorders , by Region USD N (2021-2026)
  • Table 154. Viral Gene Therapy Dermatological Disorders , by Region USD N (2021-2026)
  • Table 155. Viral Gene Therapy Metabolic Disorders , by Region USD N (2021-2026)
  • Table 156. Viral Gene Therapy Hematological Disorders , by Region USD N (2021-2026)
  • Table 157. Viral Gene Therapy Muscle-related Diseases , by Region USD N (2021-2026)
  • Table 158. Viral Gene Therapy Oncological Disorders , by Region USD N (2021-2026)
  • Table 159. Viral Gene Therapy Ophthalmic Disease , by Region USD N (2021-2026)
  • Table 160. South America Viral Gene Therapy, by Country USD N (2021-2026)
  • Table 161. South America Viral Gene Therapy, by Vector Type USD N (2021-2026)
  • Table 162. South America Viral Gene Therapy, by Distribution Channel USD N (2021-2026)
  • Table 163. South America Viral Gene Therapy, by Method USD N (2021-2026)
  • Table 164. South America Viral Gene Therapy, by Therapeutic Area USD N (2021-2026)
  • Table 165. Brazil Viral Gene Therapy, by Vector Type USD N (2021-2026)
  • Table 166. Brazil Viral Gene Therapy, by Distribution Channel USD N (2021-2026)
  • Table 167. Brazil Viral Gene Therapy, by Method USD N (2021-2026)
  • Table 168. Brazil Viral Gene Therapy, by Therapeutic Area USD N (2021-2026)
  • Table 169. Argentina Viral Gene Therapy, by Vector Type USD N (2021-2026)
  • Table 170. Argentina Viral Gene Therapy, by Distribution Channel USD N (2021-2026)
  • Table 171. Argentina Viral Gene Therapy, by Method USD N (2021-2026)
  • Table 172. Argentina Viral Gene Therapy, by Therapeutic Area USD N (2021-2026)
  • Table 173. Rest of South America Viral Gene Therapy, by Vector Type USD N (2021-2026)
  • Table 174. Rest of South America Viral Gene Therapy, by Distribution Channel USD N (2021-2026)
  • Table 175. Rest of South America Viral Gene Therapy, by Method USD N (2021-2026)
  • Table 176. Rest of South America Viral Gene Therapy, by Therapeutic Area USD N (2021-2026)
  • Table 177. Asia Pacific Viral Gene Therapy, by Country USD N (2021-2026)
  • Table 178. Asia Pacific Viral Gene Therapy, by Vector Type USD N (2021-2026)
  • Table 179. Asia Pacific Viral Gene Therapy, by Distribution Channel USD N (2021-2026)
  • Table 180. Asia Pacific Viral Gene Therapy, by Method USD N (2021-2026)
  • Table 181. Asia Pacific Viral Gene Therapy, by Therapeutic Area USD N (2021-2026)
  • Table 182. China Viral Gene Therapy, by Vector Type USD N (2021-2026)
  • Table 183. China Viral Gene Therapy, by Distribution Channel USD N (2021-2026)
  • Table 184. China Viral Gene Therapy, by Method USD N (2021-2026)
  • Table 185. China Viral Gene Therapy, by Therapeutic Area USD N (2021-2026)
  • Table 186. Japan Viral Gene Therapy, by Vector Type USD N (2021-2026)
  • Table 187. Japan Viral Gene Therapy, by Distribution Channel USD N (2021-2026)
  • Table 188. Japan Viral Gene Therapy, by Method USD N (2021-2026)
  • Table 189. Japan Viral Gene Therapy, by Therapeutic Area USD N (2021-2026)
  • Table 190. India Viral Gene Therapy, by Vector Type USD N (2021-2026)
  • Table 191. India Viral Gene Therapy, by Distribution Channel USD N (2021-2026)
  • Table 192. India Viral Gene Therapy, by Method USD N (2021-2026)
  • Table 193. India Viral Gene Therapy, by Therapeutic Area USD N (2021-2026)
  • Table 194. South Korea Viral Gene Therapy, by Vector Type USD N (2021-2026)
  • Table 195. South Korea Viral Gene Therapy, by Distribution Channel USD N (2021-2026)
  • Table 196. South Korea Viral Gene Therapy, by Method USD N (2021-2026)
  • Table 197. South Korea Viral Gene Therapy, by Therapeutic Area USD N (2021-2026)
  • Table 198. Taiwan Viral Gene Therapy, by Vector Type USD N (2021-2026)
  • Table 199. Taiwan Viral Gene Therapy, by Distribution Channel USD N (2021-2026)
  • Table 200. Taiwan Viral Gene Therapy, by Method USD N (2021-2026)
  • Table 201. Taiwan Viral Gene Therapy, by Therapeutic Area USD N (2021-2026)
  • Table 202. Australia Viral Gene Therapy, by Vector Type USD N (2021-2026)
  • Table 203. Australia Viral Gene Therapy, by Distribution Channel USD N (2021-2026)
  • Table 204. Australia Viral Gene Therapy, by Method USD N (2021-2026)
  • Table 205. Australia Viral Gene Therapy, by Therapeutic Area USD N (2021-2026)
  • Table 206. Rest of Asia-Pacific Viral Gene Therapy, by Vector Type USD N (2021-2026)
  • Table 207. Rest of Asia-Pacific Viral Gene Therapy, by Distribution Channel USD N (2021-2026)
  • Table 208. Rest of Asia-Pacific Viral Gene Therapy, by Method USD N (2021-2026)
  • Table 209. Rest of Asia-Pacific Viral Gene Therapy, by Therapeutic Area USD N (2021-2026)
  • Table 210. Europe Viral Gene Therapy, by Country USD N (2021-2026)
  • Table 211. Europe Viral Gene Therapy, by Vector Type USD N (2021-2026)
  • Table 212. Europe Viral Gene Therapy, by Distribution Channel USD N (2021-2026)
  • Table 213. Europe Viral Gene Therapy, by Method USD N (2021-2026)
  • Table 214. Europe Viral Gene Therapy, by Therapeutic Area USD N (2021-2026)
  • Table 215. Germany Viral Gene Therapy, by Vector Type USD N (2021-2026)
  • Table 216. Germany Viral Gene Therapy, by Distribution Channel USD N (2021-2026)
  • Table 217. Germany Viral Gene Therapy, by Method USD N (2021-2026)
  • Table 218. Germany Viral Gene Therapy, by Therapeutic Area USD N (2021-2026)
  • Table 219. France Viral Gene Therapy, by Vector Type USD N (2021-2026)
  • Table 220. France Viral Gene Therapy, by Distribution Channel USD N (2021-2026)
  • Table 221. France Viral Gene Therapy, by Method USD N (2021-2026)
  • Table 222. France Viral Gene Therapy, by Therapeutic Area USD N (2021-2026)
  • Table 223. Italy Viral Gene Therapy, by Vector Type USD N (2021-2026)
  • Table 224. Italy Viral Gene Therapy, by Distribution Channel USD N (2021-2026)
  • Table 225. Italy Viral Gene Therapy, by Method USD N (2021-2026)
  • Table 226. Italy Viral Gene Therapy, by Therapeutic Area USD N (2021-2026)
  • Table 227. United Kingdom Viral Gene Therapy, by Vector Type USD N (2021-2026)
  • Table 228. United Kingdom Viral Gene Therapy, by Distribution Channel USD N (2021-2026)
  • Table 229. United Kingdom Viral Gene Therapy, by Method USD N (2021-2026)
  • Table 230. United Kingdom Viral Gene Therapy, by Therapeutic Area USD N (2021-2026)
  • Table 231. Netherlands Viral Gene Therapy, by Vector Type USD N (2021-2026)
  • Table 232. Netherlands Viral Gene Therapy, by Distribution Channel USD N (2021-2026)
  • Table 233. Netherlands Viral Gene Therapy, by Method USD N (2021-2026)
  • Table 234. Netherlands Viral Gene Therapy, by Therapeutic Area USD N (2021-2026)
  • Table 235. Rest of Europe Viral Gene Therapy, by Vector Type USD N (2021-2026)
  • Table 236. Rest of Europe Viral Gene Therapy, by Distribution Channel USD N (2021-2026)
  • Table 237. Rest of Europe Viral Gene Therapy, by Method USD N (2021-2026)
  • Table 238. Rest of Europe Viral Gene Therapy, by Therapeutic Area USD N (2021-2026)
  • Table 239. MEA Viral Gene Therapy, by Country USD N (2021-2026)
  • Table 240. MEA Viral Gene Therapy, by Vector Type USD N (2021-2026)
  • Table 241. MEA Viral Gene Therapy, by Distribution Channel USD N (2021-2026)
  • Table 242. MEA Viral Gene Therapy, by Method USD N (2021-2026)
  • Table 243. MEA Viral Gene Therapy, by Therapeutic Area USD N (2021-2026)
  • Table 244. Middle East Viral Gene Therapy, by Vector Type USD N (2021-2026)
  • Table 245. Middle East Viral Gene Therapy, by Distribution Channel USD N (2021-2026)
  • Table 246. Middle East Viral Gene Therapy, by Method USD N (2021-2026)
  • Table 247. Middle East Viral Gene Therapy, by Therapeutic Area USD N (2021-2026)
  • Table 248. Africa Viral Gene Therapy, by Vector Type USD N (2021-2026)
  • Table 249. Africa Viral Gene Therapy, by Distribution Channel USD N (2021-2026)
  • Table 250. Africa Viral Gene Therapy, by Method USD N (2021-2026)
  • Table 251. Africa Viral Gene Therapy, by Therapeutic Area USD N (2021-2026)
  • Table 252. North America Viral Gene Therapy, by Country USD N (2021-2026)
  • Table 253. North America Viral Gene Therapy, by Vector Type USD N (2021-2026)
  • Table 254. North America Viral Gene Therapy, by Distribution Channel USD N (2021-2026)
  • Table 255. North America Viral Gene Therapy, by Method USD N (2021-2026)
  • Table 256. North America Viral Gene Therapy, by Therapeutic Area USD N (2021-2026)
  • Table 257. United States Viral Gene Therapy, by Vector Type USD N (2021-2026)
  • Table 258. United States Viral Gene Therapy, by Distribution Channel USD N (2021-2026)
  • Table 259. United States Viral Gene Therapy, by Method USD N (2021-2026)
  • Table 260. United States Viral Gene Therapy, by Therapeutic Area USD N (2021-2026)
  • Table 261. Canada Viral Gene Therapy, by Vector Type USD N (2021-2026)
  • Table 262. Canada Viral Gene Therapy, by Distribution Channel USD N (2021-2026)
  • Table 263. Canada Viral Gene Therapy, by Method USD N (2021-2026)
  • Table 264. Canada Viral Gene Therapy, by Therapeutic Area USD N (2021-2026)
  • Table 265. Mexico Viral Gene Therapy, by Vector Type USD N (2021-2026)
  • Table 266. Mexico Viral Gene Therapy, by Distribution Channel USD N (2021-2026)
  • Table 267. Mexico Viral Gene Therapy, by Method USD N (2021-2026)
  • Table 268. Mexico Viral Gene Therapy, by Therapeutic Area USD N (2021-2026)
  • Table 269. Research Programs/Design for This Report
  • Table 270. Key Data Information from Secondary Sources
  • Table 271. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Viral Gene Therapy: by Vector Type USD N (2016-2021)
  • Figure 5. Global Viral Gene Therapy: by Distribution Channel USD N (2016-2021)
  • Figure 6. Global Viral Gene Therapy: by Method USD N (2016-2021)
  • Figure 7. Global Viral Gene Therapy: by Therapeutic Area USD N (2016-2021)
  • Figure 8. South America Viral Gene Therapy Share (%), by Country
  • Figure 9. Asia Pacific Viral Gene Therapy Share (%), by Country
  • Figure 10. Europe Viral Gene Therapy Share (%), by Country
  • Figure 11. MEA Viral Gene Therapy Share (%), by Country
  • Figure 12. North America Viral Gene Therapy Share (%), by Country
  • Figure 13. Global Viral Gene Therapy share by Players 2021 (%)
  • Figure 14. Global Viral Gene Therapy share by Players (Top 3) 2021(%)
  • Figure 15. Global Viral Gene Therapy share by Players (Top 5) 2021(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Biogen (United States) Revenue, Net Income and Gross profit
  • Figure 18. Biogen (United States) Revenue: by Geography 2021
  • Figure 19. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. Novartis AG (Switzerland) Revenue: by Geography 2021
  • Figure 21. Gilead Sciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Gilead Sciences, Inc. (United States) Revenue: by Geography 2021
  • Figure 23. Spark Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Spark Therapeutics, Inc. (United States) Revenue: by Geography 2021
  • Figure 25. Orchard Therapeutics plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. Orchard Therapeutics plc. (United Kingdom) Revenue: by Geography 2021
  • Figure 27. MolMed S.p.A. (Italy) Revenue, Net Income and Gross profit
  • Figure 28. MolMed S.p.A. (Italy) Revenue: by Geography 2021
  • Figure 29. AnGes, Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 30. AnGes, Inc. (Japan) Revenue: by Geography 2021
  • Figure 31. Bluebird bio, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Bluebird bio, Inc. (United States) Revenue: by Geography 2021
  • Figure 33. Human Stem Cells Institute (Russia) Revenue, Net Income and Gross profit
  • Figure 34. Human Stem Cells Institute (Russia) Revenue: by Geography 2021
  • Figure 35. Dynavax Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 36. Dynavax Technologies (United States) Revenue: by Geography 2021
  • Figure 37. Global Viral Gene Therapy: by Vector Type USD N (2021-2026)
  • Figure 38. Global Viral Gene Therapy: by Distribution Channel USD N (2021-2026)
  • Figure 39. Global Viral Gene Therapy: by Method USD N (2021-2026)
  • Figure 40. Global Viral Gene Therapy: by Therapeutic Area USD N (2021-2026)
  • Figure 41. South America Viral Gene Therapy Share (%), by Country
  • Figure 42. Asia Pacific Viral Gene Therapy Share (%), by Country
  • Figure 43. Europe Viral Gene Therapy Share (%), by Country
  • Figure 44. MEA Viral Gene Therapy Share (%), by Country
  • Figure 45. North America Viral Gene Therapy Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Biogen (United States)
  • Novartis AG (Switzerland)
  • Gilead Sciences, Inc. (United States)
  • Spark Therapeutics, Inc. (United States)
  • Orchard Therapeutics plc. (United Kingdom)
  • MolMed S.p.A. (Italy)
  • AnGes, Inc. (Japan)
  • Bluebird bio, Inc. (United States)
  • Human Stem Cells Institute (Russia)
  • Dynavax Technologies (United States)
Additional players considered in the study are as follows:
Akcea Therapeutics (United States) , Alnylam Pharmaceuticals, Inc. (United States) , Jazz Pharmaceuticals, Inc. (Ireland)
Select User Access Type

Key Highlights of Report


Jul 2021 247 Pages 59 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Viral Gene Therapy Market Quantitative research analysis
Global Viral Gene Therapy Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Viral Gene Therapy study can be customized to meet your requirements. The market size breakdown by type [], by end use application [].
The Viral Gene Therapy Market is gaining popularity and expected to see strong valuation by 2026.
According to AMA, the Global Viral Gene Therapy market is expected to see growth rate of %.

Know More About Global Viral Gene Therapy Market Report?

Have a Query? Click Here

Other Related Reports

Canker Sores Drug Comprehensive Study by Type (Ointment, Spray, Pills, Patch, Mouthwash), Application (Hospital, Clinics, Drug Store), Packaging Type (Plastic, Aluminum, PE bottles, Glass, Others), F...
$ 3450
Scalp Care Treatment Comprehensive Study by Type (Medicated, Non-Medicated), Drug Type (Branded, Generics), Distribution Channel (Supermarket, Specialty Store, Pharmacy Store, Conventional Stores, On...
$ 3750
Stool Softeners Comprehensive Study by Type (Soft gel capsules, Oral liquids, Tablet, Chewable, Flake, Powder, Others), Distribution Channel (Pharmacy Stores, Online Stores, Hospitals, Clinics, Other...
$ 3450
Coccidiosis Treatment Comprehensive Study by Type (Sulfadimethoxine, Sulfaguanidine, Furazolidone, Trimethoprim/Sulfonamide, Others), Application (Poultry, Dog, Fish, Cat, Cattle, Others), Consumptio...
$ 3450
Scleroderma Therapy Comprehensive Study by Type (Immunosuppressors, Endothelin Receptor Antagonists, Phosphodiesterase 5 Inhibitors - PHA, Calcium Channel Blockers, Analgesic, Prostacyclin Analogues,...
$ 3650
Vaccine Shippers Comprehensive Study by Type (Insulated Shippers, Insulated Containers, Refrigerants), Application (Pharma, Biopharma), Type (Active Systems, Passive Systems), Usability Type (Single,...
$ 3500